TNF-based isolated hepatic perfusion

Frontiers in Bioscience

Volumn 14, Issue 5, 2009, Pages 1771-1784

  Bellavance, Emily C ^a   Alexander Jr , H Richard ^a,b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Colorectal carcinoma; Hepatocellular carcinoma; Hyperthermia; Isolation perfusion; Liver metastases; Neuroendocrine tumor; Ocular melanoma; Regional chemotherapy; Review

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

HUMAN; LIVER TUMOR; METASTASIS; NEOPLASM; PATHOLOGY; PERFUSION; REVIEW;

HUMANS; LIVER NEOPLASMS; NEOPLASMS; PERFUSION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 63849231788     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3339     Document Type: Article

References (86)

1. William Jarnagin, Methat Gonen, Yuman Fong, Ronald DeMatteo, Leah Ben Porat, Sarah Little, Carlos Corvera, Sharon Weber, and Leslie Blumgart: Improvement in perioperative outcome after hepatic resection: analysis of 1, 803 consecutive cases over the past decade. Annals of Surgery 236, 397-406 (2002).
2. Elizabeth Feldman, Peter Wu, Michael Gnant, David Bartlett, Steven Libutti, James Pingpank, and Richard Alexander: Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J GI Surg 8, 200-207 (2004). (Pubitemid 38228465)
3. Josep Llovet, Andrew Burroughs, and Jordi Bruix: Hepatocellular carcinoma. Lancet 362, 1907-1917 (2003). (Pubitemid 37518510)
4. Andrew Zhu, Lawrence. Blaszkowsky, David Ryan, Jeffrey Clark, Alona Muzikansky, Kerry Horgan, Susan Sheehan, Kelly Hale, Peter Enzinger, Pankaj Bhargava, and Keith Stuart: Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology 24, 1898-1903 (2006). (Pubitemid 46638989)
5. Geoffrey Falkson, Charles Moertel, Phillip Lavin, Florence Pretorius, and Paul. Carbone: Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer 42, 2149-2156 (1978). (Pubitemid 9125868)
6. R. T. Chlebowski, A. Brzechwa-Adjukiewicz, A. Cowden, J. B. Block, M. Tong, and K.K. Chan: Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat. Rep. 68, 487-491 (1984). (Pubitemid 14134096)
7. Z. Guan, Y. Wang, S. Maoleekoonpairoj, Z. Chen, W.S. Kim, V. Ratanatharathorn, W. H. Reece, T. W. Kim, and M. Lehnert: Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. British Journal of Cancer 89, 1865-1869 (2003). (Pubitemid 37533261)
8. D. Singhal, T.M. van Gulik, and D. J. Gouma: Palliative management of hilar cholangiocarcinoma. Surg. Oncol. 14, 59-74(2005). (Pubitemid 41207193)
9. Christopher Anderson, C. Wright Pinson, Jordan Berlin, and Ravi Chari: Diagnosis and treatment of cholangiocarcinoma. Oncologist 9, 43-57 (2004). (Pubitemid 38134013)
10. Ahmedin Jemal, Rebecca Siegel, Elizabeth Ward, Taylor Murray, Jiaquan Xu, Carol Smigal, and Michael Thun: Cancer Statistics 2006. CA Cancer Journal for Clinicians 56, 106-130 (2006).
11. Timothy Pawlik and Michael Choti: Surgical therapy for colorectal metastases to the liver. J. Gastrointest. Surg. 11 1057-1077 (2007).
12. C. H. Kohne, C.E. van, J. Wils, C. Bokemeyer, M. El-Serafi, M. P. Lutz, M. Lorenz, P. Reichardt, H. Ruckle-Lanz, N. Frickhofen, R. Fuchs, H. G. Mergenthaler, T. Langenbuch, U. Vanhoefer, P. Rougier, R. Voigtmann, L. Muller, B. Genicot, O. Anak, and B. Nordlinger: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. Journal of Clinical Oncology 23 4856-4865 (2005). (Pubitemid 46223990)
13. J. Y. Douillard, D. Cunningham, A. D. Roth, M.Navarro, R. D. James, P. Karasek, P. Jandik, T. Iveson, J. Carmichael, M. Alakl, G. Gruia, L. Awad, and P. Rougier: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355, 1041-1047 (2000). (Pubitemid 30162806)
14. James Lee and Edward Chiu: An update on treatment advances for the first-line therapy of metastatic colorectal cancer. Cancer J 13, 276-281 (2007).
15. J. C. Becker, P. Terheyden, E. Kampgen, S. Wagner, C. Neumann, D. Schadendorf, A. Steinmann, G. Wittenberg, W. Lieb, and E. B. Brocker: Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. British Journal of Cancer 87, 840-845 (2002). (Pubitemid 35252958)
16. Evangolos Gragoudas, Kathleen Egan, Johanna Seddon, Robert. Glynn, Sandra Walsh, Susan Finn, John Munzenrider, and M. Spar: Survival of patients with metastases from uveal melanoma. Ophthalmology 98, 383-390 (1991).
17. Elizabeth Feldman, James Pingpank, and Richard Alexander: Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol. 11, 290-297 (2004). (Pubitemid 40486769)
18. Seppo Pyrhonen: The treatment of metastatic uveal melanoma. European Journal of Cancer 34 Suppl 3:S27-S30., S27-S30 (1998). (Pubitemid 28430606)
19. Serge Leyvraz, Vito Spataro, Jean Bauer, Sandra Pampallona, Remy Salmon, Thierry Dorval, Reto Meuli, Michel Gillet, Ferdy Lejeune, and Leonidas Zografos: Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. Journal of Clinical Oncology 15, 2589-2595 (1997). (Pubitemid 27289889)
20. R. Arnold, M. E. Trautmann, W. Creutzfeldt, R. Benning, M. Benning, C. Neuhaus, R. Jürgensen, K. Stein, H. Schäfer, C. Bruns, and H.-J. Dennler: Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38, 430-438 (1996).
21. Robert Sutcliffe, Donal Maguire, John Ramage, Mohamed Rela, and Nigel Heaton: Management of neuroendocrine liver metastases. Am J Surg 187, 39-46 (2004). (Pubitemid 38045501)
22. Boris Kuvshinoff and Yuman Fong: Surgical therapy of liver metastases. Seminars in Oncology 34, 177-185 (2007). (Pubitemid 46874549)
23. Steven Curley, Francesco Izzo, Eddie Abdalla, and J. Nicholas Vauthey: Surgical treatment of colorectal cancer metastasis. Cancer Metastasis Rev 23, 165-182 (2004). (Pubitemid 38221602)
24. Stefaan Mulier, Yicheng Ni, Jacques Jamart, Theo Ruers, Guy Marchal, and Luc Michel: Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Annals of Surgery 242, 158-171 (2005). (Pubitemid 41033431)
25. W. Y. Lau, T. W. Leung, S. C. Yu, and S. K. Ho: Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Annals of Surgery 237, 171-179 (2003). (Pubitemid 38173243)
26. Josep Llovet and Jordi Bruix: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37, 429-442 (2003). (Pubitemid 36152543)
27. John Touzios, James Kiely, Susan Pitt, William Rilling, Edward Quebbeman, Stuart Wilson, and Henry Pitt: Neuroendocrine hepatic metastases: does aggressive management improve survival? Annals of Surgery 241, 776-783 (2005).
28. N. B. Ackerman, W. M. Lien, and N. A. Silverman: The blood supply of experimental liver metastases. III. The effects of acute ligation of the hepatic artery or portal vein. Surgery 71, 636-641 (1972).
29. Dominique Elias, Thierry de Baere, Lucas Sideris, and Michel Ducreux: Regional chemotherapeutic techniques for liver tumors: current knowledge and future directions. Surgical Clinics of North America 84, 607-625 (2004). (Pubitemid 38388286)
30. Robert. Ausman and J. Bradley Aust: Isolated perfusion of the liver with HN2. Surgical Forum 10, 77-79 (1960).
31. Anthony Asher, James Mulé, Cheryl Reichert, Eitan Shiloni, and Steven Rosenberg: Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. Journal of Immunology 138, 963-974 (1987). (Pubitemid 17012421)
32. Amelia Grover and Richard Alexander: The past decade of experience with isolated hepatic perfusion. Oncologist 9, 653-664 (2004). (Pubitemid 39546406)
33. David Bartlett, Steven Libutti, William Figg, Douglas Fraker, and Richard Alexander: Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 129, 176-187 (2001).
34. Richard Alexander, David Bartlett, and Steven Libutti: Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. The Oncologist 5, 416-424 (2000).
35. P. Lindner, M. Fjalling, L. Hafstrom, H. Nielsen, and H. Mattson: Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia tumour necrosis factor alpha and melphalan. Eur J Surg Oncol, 25, 179-185 (1999). (Pubitemid 29182461)
36. Richard Alexander and Andrew Feldman: Tumor necrosis factor: Basic principles and clinical application in systemic and regional cancer treatment, In: Biologic Therapy of Cancer. Ed: Rosenberg S, Lippincott Williams and Wilkins, PA (2000).
37. K. Kitamura, H. Kuwano, H. Matsuda, Y. Toh, H. Masuda, and K. Sugimachi: Synergistic effects of intratumor administration of cis- diamminedichloroplatinum(II) combined with local hyperthermia in melanoma bearing mice. J Surg Oncol 51, 188-194 (1992).
38. R. C. Miller, M. Richards, C. Baird, S. Martin, and E. J. Hall: Interaction of hyperthermia and chemotherapy agents; cell lethality and oncogenic potential. International Journal of Hyperthermia 10, 89-99 (1994). (Pubitemid 24030725)
39. Lloyd Old: Tumor necrosis factor (TNF). Science 230, 630-632 (1985).
40. M. J. Shear, F. C. Turner, A. Perrault, and J. Shorelton: Chemical treatment of tumors. V. Isolation of the hemorrhageproducing fraction from serratia marcescens (Bacillus prodigiosus) culture filtrate. Journal of the National Cancer Institute 81-97 (1943).
41. Murray Shear: Chemical treatment of tumors, IX. Reactions of mice with primary subcutaneous tumors to injection of a hemorrhage-producing bacterial polysaccharide. Journal of the National Cancer Institute 4, 461-476 (1944).
42. William. O'Malley, Betty Achinstein, and Murray Shear: Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance. Nutr Rev 46, 389-391 (1988).
43. E. M. Hersh, B. S. Metch, F. M. Muggia, T. D. Brown, R. P. Whitehead, G. T. Budd, J.J. Rinehart, E.D. Crawford, J.D. Bonnet, and B.C. Behrens: Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: A summary of the Southwest Oncology Group experience. Journal of Immunotherapy 10, 426-431 (1991).
44. H. Gamm, A. Lindemann, R. Mertelsmann, and F. Herrmann: Phase I trial of recombinant human tumour necrosis factor □ in patients with advanced malignancy. European Journal of Cancer 27, 856-863 (1991).
45. Kiyo Kimura, Tetsuo Taguchi, Ichiro Urushizaki, Ryuzo Ohno, Ohno Abe, Hisashi Furue, Takao Hattori, Hidehito Ichihashi, Kiyoshi Inoguchi, Hisashi Majima, Hisanobu Niitani, Kazuo Ota, Tatsuo Saito, Shoji Suga, Yozo Suzuoki, Akira Wakui, and Kazumasa Yamada: Phase I study of recombinant human tumor necrosis factor. Cancer Chemotherapy and Pharmacology 20, 223-229 (1987). (Pubitemid 17163399)
46. Joan Schiller, Barry. Storer, Patricia. Witt, Dona Alberti, Mary Beth Tombes, Rhoda Arzoomanian, Richard Proctor, Donna McCarthy, Raymond Brown, Stephen Voss, Scott Remick, Jean Grem, Ernest Borden, and Donald Trump: Biological and clinical effects of intravenous tumor necrosis factor-□ administered three times weekly. Cancer Res 51, 1651-1658 (1991).
47. Edward Creagan, John Kovach, Charles Moertel, Stephen Frytak, and Larry Kvols: A phase I clinical trial of recombinant human tumor necrosis factor. Cancer, 62, 2467-2471 (1988). (Pubitemid 19006423)
48. Danielle Lienard, Patricia Ewalenko, Jean-Jacques Delmotti, Nathalie Renard, and Ferdy Lejeune: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10, 52-60 (1992).
49. Alexander Eggermont, F. Brunstein, D. Grunhagen, and Timo ten Hagen: Regional treatment of metastasis: role of regional perfusion. State of the art isolated limb perfusion for limb salvage. Ann.Oncol 15 Suppl 4, iv107-112 (2004). (Pubitemid 39585321)
50. Douglas Fraker, Richard Alexander, David Bartlett, and Steven Rosenberg: A prospective randomized trial of therapeutic isolated limb perfusion (ILP) comparing melphalan (M) versus melphalan, tumor necrosis factor (TNF) and interferon-gamma (IFN): An initial report. Society of Surgical Oncology 49, 6 (1996).
51. Mitchell Posner, Danielle Lienard, Ferdy Lejeune, D. Rosenfelder, and J. Kirkwood: Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor (TNF) alone for metastatic intransit melanoma. ASCO 13, 396 (1994).
52. Richard Alexander: Isolation Perfusion. In: Cancer: Principles & Practice of Oncology. Eds: Devita V, Hellman S, Rosenberg S, Lippincott Williams and Wilkins, PA (2005).
53. Remso van Horssen, Timo ten Hagen, and Alexander Eggermont: TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11, 397-408 (2006).
54. Ikuo Takahashi, Yasunori Emi, Shota Hasuda, Yoshihiro Kakeji, Yoshihiko Maehara and Keizo Sugimachi: Clinical application of hyperthermia combined with anticancer drugs for the treatment of solid tumors. Surgery 131, S78-S84 (2002). (Pubitemid 34118620)
55. Jerold Brett, Herwig Gerlach, Peter Nawroth, S Steinberg, G. Godman, and D. Stern: Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med 169, 1977-1991 (1989). (Pubitemid 19162960)
56. Herwig Gerlach, Howard Lieberman, Ronald Bach, Gabriel Godman, Jerold Brett, and David Stern: Enhanced responsiveness of endothelium in the growing/motile state to tumor necrosis factor/cachectin. J Exp Med, 170, 913-931 (1989). (Pubitemid 19226673)
57. K.S. Mark and D.W. Miller: Increased permeability of primary cultured brain microvessel endothelial cell monolayers following TNF-alpha exposure. Life Sciences 64, 1941-1953 (1999). (Pubitemid 29215195)
58. Richard Alexander, Charles Brown, David Bartlett, Steven Libutti, William Figg, Sangeeta Raje, and Ewa Turner: Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor independent mechanisms. Clin Cancer Res 4, 2362 (1998).
59. Boudewijn van Etten, Mark de Vries, Marc van Ijken, Titia Lans, Gunter Guetens, G Ambagtsheer, Sandra van Tiel, Gert de Boeck, Ernst de Bruijn, Alexander Eggermont, and Timo ten Hagen: Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion. British Journal of Cancer 88, 314-319 (2003). (Pubitemid 36255853)
60. Peter Nawroth, Dan Handley, Gary Matsueda, Robert de Waal, Herwig Gerlach, Dietmar Blohm, and David Stern: Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J Exp Med 168, 637-647 (1988).
61. Peter Nawroth and David Stern: Modulation of endothelial cell hemostatic properties by tumor necrosis factor. Journal of Experimental Medicine 163, 740-745 (1986). (Pubitemid 16141974)
62. Angelika Bierhaus, Youming Zhang, Youhua Deng, Nigel Mackman, Peter Quehenberger, Michael Haase, Thomas Luther, M.arin Muller, Hubert Bohrer, and Johannes Greten: Mechanism of the tumor necrosis factor alpha-mediated induction of endothelial tissue factor. J Biol Chem 270, 26419-26432 (1995).
63. Josef Friedl, Markus Puhlmann, David Bartlett, Steven Libutti, Ewa Turner, Michael Gnant, and Richard Alexander: Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF Blood 100, 1334-1339 (2002). (Pubitemid 34864289)
64. Douglas Fraker and Michael Soulen: Regional therapy of hepatic metastases Hematol Oncol Clin North Am 16, 947-967 (2002). (Pubitemid 35215833)
65. Steven Libutti, David Bartlett, Douglas Fraker, and Richard Alexander: Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. Journal of the American College of Surgeons 191, 519-530 (2000).
66. Paul Lindnér, Martha Fjälling, Larsolof Hafström, H Kierulff-Nielsen, Jonas Mattsson, Tore Scherstén, Magnus Rizell, and Peter Naredi: Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. Eur J Surg Oncol 25, 179-185 (1999). (Pubitemid 29182461)
67. Karl Schwemmle, Kristian Link, and Bernd Rieck: Rationale and indications for perfusion in liver tumors: Current data. World Journal of Surgery 11, 534-540 (1987). (Pubitemid 17137109)
68. Joost Rothbarth, Milan Pijl, Alexander Vahrmeijer, Henk Hartgrink, Fred Tijl, Peter Kuppen, Rob Tollenaar, and Cornelis van de Velde: Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. British Journal of Surgery 90, 1391-1397 (2003). (Pubitemid 37421675)
69. Richard Alexander, David Bartlett, Steven Libutti, Douglas Fraker, Tammy Moser, and Steven Rosenberg: Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 16, 1479-1489 (1998). (Pubitemid 28175769)
70. Richard Alexander, Steven Libutti, David Bartlett, James Pingpank, Karen Kranda, Cynthia Helsabeck, and Tatiana Beresnev: Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. Cancer 95, 730-736 (2002). (Pubitemid 34839663)
71. Leo van Iersel, Mariette Verlaan, Alexander Vahrmeijer, Els van Persijn van Meerten, Fred Tijl, Richard Sparidans, Harald Gelderblom, Peter Kuppen, Rob.Tollenaar, and Cornelis van de Velde: Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: A clinical and pharmacologic evaluation. European Journal of Surgical Oncology 33, 874-881 (2007). (Pubitemid 47279055)
72. Dimitrios Kehagias, Lia Moulopoulos, Vassilios Smirniotis, Agathi Pafiti, Stamos Ispanopoulos, and Lampos Vlahos: Imaging findings in primary carcinoid tumour of the liver with gastrin production. British Journal of Radiology 72, 207-209 (1999). (Pubitemid 29095070)
73. Titia Lans, David Bartlett, Steven Libutti, Michael Gnant, David Liewehr, David Venzon, Ewa Turner, and Richard Alexander: Role of tumor necrosis factor (TNF) on toxicity and cytokine production following isolated hepatic perfusion (IHP). Clinical Cancer Research 7, 784-790 (2001). (Pubitemid 32708710)
74. Erick Hack, Ronald De Groot, Richelle Felt-Bersma, Jan Nuijens, Robertus Straak van Schijndel, Anke. Eerenberg-Belmer, Lambertus Thijs, and Lucien Aarden: Increased plasma levels of interleukin-6 in sepsis. Blood 74, 1704-1710 (1989). (Pubitemid 19251549)
75. Erick Hack, Magreet Hart, Robertus Straak.van Schijndel, Anke Eerenberg, Jan Nuijens, Lambertus Thijs, and Lucien Aarden: Interleukin-8 sepsis: Relation to shock and inflammatory mediators. Infect Immun 60, 2835-2842 (1992).
76. Cornelia Marty, Benoit Misset, Fabienne Tamion, Catherine Fitting, Jean Carlet, and Jean-Marc Cavaillon: Circulating interleukin-8 concentrations in patients with multiple organ failure of septic and nonseptic origin. Critical Care Medicine, 22, 673-679 (1994). (Pubitemid 24121570)
77. Pierre Damas, Didier Ledoux, Monique Nys, Yvonne Vrindts, Donat de Groote, Paul Franchimont, and Maurice Lamy: Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Annals of Surgery 215, 356-362 (1992).
78. Harry Moscovitz, Frances Shofer, Harold Mignott, Amy Behrman, and Laura Kilpatrick: Plasma cytokine determinations in emergency department patients as a predictor of bacteremia and infectious disease severity. Critical Care Medicine 22, 1102-1107 (1994). (Pubitemid 24219415)
79. Mark de Vries, Inne Borel, Anton Swaak, Erick Hack, Cornelis van de Velde, Theo Wiggers, Rob Tollenaar, Peter Kuppen, and Alexander Eggermont: Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases. Eur. J. Clin.Invest 29, 553-560 (1999). (Pubitemid 29271647)
80. Richard Alexander, Steven Libutti, James Pingpank, David Bartlett, Cynthia Helsabeck, and Tatiana Beresneva: Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol 12, 138-144 (2005). (Pubitemid 40486622)
81. Karl Oldhafer, Markus Frerker, Hauke Lang, Joachim Fauler, Peer Flemming, Ekkehard Schmoll, Silvio Nadalin, Laura Moreno, and Rudolf Pichlmayr: High-dose mitomycin C in isolated hyperthermic liver perfusion for unresectable liver metastases. J Invest Surg 11, 393-400 (1998). (Pubitemid 29021150)
82. Richard Alexander, Steven Libutti, David Bartlett, Markus Puhlmann, Douglas Fraker, and Lisa Bachenheimer: A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 6, 3062-3070 (2000). (Pubitemid 30637729)
83. Amelia Grover, Steven Libutti, James Pingpank, Cynthia Helsabeck, Tatiana Beresnev, and Richard Alexander, Jr.: Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. Surgery 136, 1176-1182 (2004). (Pubitemid 39647531)
84. Elizabeth Feldman, Peter Wu, Tatiana Beresneva, Cynthia Helsabeck, Montessa Rodriguez, David Bartlett, Steven Libutti, James Pingpank, and Richard Alexander: Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J Gastrointest Surg 8, 200-207 (2004). (Pubitemid 38228465)
85. Mario Lise, Pierluigi Pilati, Pierpaolo Da Pian, Simone Mocellin, Carlo Ori, Dario Casara, Carlo Rossi, Tanya Darisi, Susanna Corazzina, and Donato Nitti: Hyperthermic isolated liver perfusion for unresectable liver cancers: pilot study. J Chemother 16 Suppl 5, 37-39 (2004). (Pubitemid 40052987)
86. Larsolof Hafström, Stig Holmberg, Peter Naredi, Paul Lindnér, Ann Bengtsson, Goran Tidebrant, and T Scherstén: Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surgical Oncology 3, 103-108 (1994). (Pubitemid 24237137)